UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition

Journal of neurology, 2021-04, Vol.268 (4), p.1210-1221

2021

Volltextzugriff (PDF)

The role of TH17 cells in multiple sclerosis: Therapeutic implications

Autoimmunity reviews, 2020-10, Vol.19 (10), p.102647, Article 102647

2020

Volltextzugriff (PDF)

Natalizumab during pregnancy and lactation

Multiple sclerosis, 2018-10, Vol.24 (12), p.1627-1634

2018

Volltextzugriff (PDF)

The need for a strategic therapeutic approach: multiple sclerosis in check

Therapeutic Advances in Chronic Disease, 2022-01, Vol.13, p.20406223211063032-20406223211063032

2022

Volltextzugriff (PDF)

Letter to the editor regarding “Therapeutic drug monitoring of natalizumab”

Multiple sclerosis, 2020-05, Vol.26 (6), p.741-742

2020

Volltextzugriff (PDF)

Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis

Frontiers in immunology, 2024-06, Vol.15, p.1404316

2024

Volltextzugriff (PDF)

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation

Frontiers in immunology, 2021-08, Vol.12, p.715195-715195

2021

Volltextzugriff (PDF)

Should We Use Clinical Tools to Identify Disease Progression?

Frontiers in neurology, 2021-01, Vol.11, p.628542-628542

2021

Volltextzugriff (PDF)

Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects

Cells (Basel, Switzerland), 2021-11, Vol.10 (11), p.3177

2021

Volltextzugriff (PDF)

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation

Journal of neuroinflammation, 2017-02, Vol.14 (1), p.41-41, Article 41

2017

Volltextzugriff (PDF)

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients

Frontiers in immunology, 2018-11, Vol.9, p.2669-2669

2018

Volltextzugriff (PDF)

Influence of Pre-Analytic Conditions on Quantity of Lymphocytes

International journal of molecular sciences, 2023-09, Vol.24 (17), p.13479

2023

Volltextzugriff (PDF)

Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination

Multiple sclerosis, 2023-12, Vol.29 (14), p.1849-1859

2023

Volltextzugriff (PDF)

Letter to the editor on the paper: “The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Multiple sclerosis, 2018-05, Vol.24 (6), p.820-822

2018

Volltextzugriff (PDF)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

Frontiers in neurology, 2021-04, Vol.12, p.650530-650530

2021

Volltextzugriff (PDF)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up

Frontiers in neurology, 2018-12, Vol.9, p.1071-1071

2018

Volltextzugriff (PDF)

Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?

Multiple sclerosis, 2018-09, Vol.24 (10), p.1337-1346

2018

Volltextzugriff (PDF)

Influence of exercise on quantity and deformability of immune cells in multiple sclerosis

Frontiers in neurology, 2023-05, Vol.14, p.1148106-1148106

2023

Volltextzugriff (PDF)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

Therapeutic advances in neurological disorders, 2023-01, Vol.16, p.17562864221150040-17562864221150040

2023

Volltextzugriff (PDF)

Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication

Neurological research and practice, 2023-08, Vol.5 (1), p.48-48, Article 48

2023

Volltextzugriff (PDF)

SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma

Vaccines (Basel), 2024-06, Vol.12 (6), p.684

2024

Volltextzugriff (PDF)

Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort

Vaccines (Basel), 2024-03, Vol.12 (3), p.265

2024

Volltextzugriff (PDF)

Pilot study on the influence of acute alcohol exposure on biophysical parameters of leukocytes

Frontiers in molecular biosciences, 2023-08, Vol.10, p.1243155-1243155

2023

Volltextzugriff (PDF)

Consensus quality indicators for monitoring multiple sclerosis

The Lancet regional health. Europe, 2024-05, Vol.40, p.100891-100891, Article 100891

2024

Volltextzugriff (PDF)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting

Therapeutic advances in chronic disease, 2019, Vol.10, p.2040622319835136-2040622319835136

2019

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(31)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition

The role of TH17 cells in multiple sclerosis: Therapeutic implications

Natalizumab during pregnancy and lactation

The need for a strategic therapeutic approach: multiple sclerosis in check

Letter to the editor regarding “Therapeutic drug monitoring of natalizumab”

Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation

Should We Use Clinical Tools to Identify Disease Progression?

Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation

Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients

Influence of Pre-Analytic Conditions on Quantity of Lymphocytes

Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination

Letter to the editor on the paper: “The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up

Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?

Influence of exercise on quantity and deformability of immune cells in multiple sclerosis

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication

SARS-CoV-2-Specific Immune Cytokine Profiles to mRNA, Viral Vector and Protein-Based Vaccines in Patients with Multiple Sclerosis: Beyond Interferon Gamma

Insights from Real-World Practice: The Dynamics of SARS-CoV-2 Infections and Vaccinations in a Large German Multiple Sclerosis Cohort

Pilot study on the influence of acute alcohol exposure on biophysical parameters of leukocytes

Consensus quality indicators for monitoring multiple sclerosis

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting

Suchergebnisse filtern